BIOMAT Database Logo BIOMAT Database Logo

Design and synthesis of new indanol-1,2,3-triazole derivatives as potent antitubercular and antimicrobial agents. 2020

Pramod S Phatak, and Rajubai D Bakale, and Ravibhushan S Kulkarni, and Sambhaji T Dhumal, and Prashant P Dixit, and Vagolu Siva Krishna, and Dharmarajan Sriram, and Vijay M Khedkar, and Kishan P Haval
Department of Chemistry, Dr. Babasaheb Ambedkar Marathwada University SubCampus, Osmanabad 413 501, MS, India.

In a search of new antitubercular agents, herein we have reported a series of new thirty-two indanol-1,2,3-triazole derivatives. The synthesized compounds were screened for their in vitro antitubercular and antimicrobial activities. Among the screened compounds, most of the compounds have displayed good antitubercular activity against Mycobacterium tuberculosis H37Rv. The compound 5g has been identified as potent antitubercular agent with MIC value 1.56 µM. The most active compounds of the series were further studied for their cytotoxicity against HEK 293 cells using MTT assay and found to be nontoxic. In addition, ten compounds were shown good antimicrobial activities against both antibacterial and antifungal pathogens. A molecular docking study against Mycobacterial enoyl-ACP-reductase (InhA) was performed to gain an insight into the molecular mechanism of antitubercular action. The pharmacokinetic parameters of these compounds were studied and displayed acceptable drug-likeness score.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D057809 HEK293 Cells A cell line generated from human embryonic kidney cells that were transformed with human adenovirus type 5. 293T Cells,HEK 293 Cell Line,HEK 293 Cells,Human Embryonic Kidney Cell Line 293,Human Kidney Cell Line 293,293 Cell, HEK,293 Cells, HEK,293T Cell,Cell, 293T,Cell, HEK 293,Cell, HEK293,Cells, 293T,Cells, HEK 293,Cells, HEK293,HEK 293 Cell,HEK293 Cell

Related Publications

Pramod S Phatak, and Rajubai D Bakale, and Ravibhushan S Kulkarni, and Sambhaji T Dhumal, and Prashant P Dixit, and Vagolu Siva Krishna, and Dharmarajan Sriram, and Vijay M Khedkar, and Kishan P Haval
Design, synthesis and in silico molecular docking evaluation of novel 1,2,3-triazole derivatives as potent antimicrobial agents.
April 2024, Heliyon,
Pramod S Phatak, and Rajubai D Bakale, and Ravibhushan S Kulkarni, and Sambhaji T Dhumal, and Prashant P Dixit, and Vagolu Siva Krishna, and Dharmarajan Sriram, and Vijay M Khedkar, and Kishan P Haval
Synthesis of new thiazolyl-pyrazolyl-1,2,3-triazole derivatives as potential antimicrobial agents.
October 2019, European journal of medicinal chemistry,
Pramod S Phatak, and Rajubai D Bakale, and Ravibhushan S Kulkarni, and Sambhaji T Dhumal, and Prashant P Dixit, and Vagolu Siva Krishna, and Dharmarajan Sriram, and Vijay M Khedkar, and Kishan P Haval
Synthesis of 1,2,3-triazole-thymol derivatives as potential antimicrobial agents.
October 2022, Heliyon,
Pramod S Phatak, and Rajubai D Bakale, and Ravibhushan S Kulkarni, and Sambhaji T Dhumal, and Prashant P Dixit, and Vagolu Siva Krishna, and Dharmarajan Sriram, and Vijay M Khedkar, and Kishan P Haval
New tetrazolopyrrolidine-1,2,3-triazole analogues as potent anticancer agents: design, synthesis and molecular docking studies.
November 2023, Molecular diversity,
Pramod S Phatak, and Rajubai D Bakale, and Ravibhushan S Kulkarni, and Sambhaji T Dhumal, and Prashant P Dixit, and Vagolu Siva Krishna, and Dharmarajan Sriram, and Vijay M Khedkar, and Kishan P Haval
Design and synthesis of novel pyrimidine derivatives as potent antitubercular agents.
February 2019, European journal of medicinal chemistry,
Pramod S Phatak, and Rajubai D Bakale, and Ravibhushan S Kulkarni, and Sambhaji T Dhumal, and Prashant P Dixit, and Vagolu Siva Krishna, and Dharmarajan Sriram, and Vijay M Khedkar, and Kishan P Haval
Design, synthesis and mechanistic study of new 1,2,4-triazole derivatives as antimicrobial agents.
June 2021, Bioorganic chemistry,
Pramod S Phatak, and Rajubai D Bakale, and Ravibhushan S Kulkarni, and Sambhaji T Dhumal, and Prashant P Dixit, and Vagolu Siva Krishna, and Dharmarajan Sriram, and Vijay M Khedkar, and Kishan P Haval
Design and synthesis, biological evaluation of bis-(1,2,3- and 1,2,4)-triazole derivatives as potential antimicrobial and antifungal agents.
June 2021, Bioorganic & medicinal chemistry letters,
Pramod S Phatak, and Rajubai D Bakale, and Ravibhushan S Kulkarni, and Sambhaji T Dhumal, and Prashant P Dixit, and Vagolu Siva Krishna, and Dharmarajan Sriram, and Vijay M Khedkar, and Kishan P Haval
Design, synthesis and biological evaluation of tacrine-1,2,3-triazole derivatives as potent cholinesterase inhibitors.
January 2018, MedChemComm,
Pramod S Phatak, and Rajubai D Bakale, and Ravibhushan S Kulkarni, and Sambhaji T Dhumal, and Prashant P Dixit, and Vagolu Siva Krishna, and Dharmarajan Sriram, and Vijay M Khedkar, and Kishan P Haval
Synthesis and antimicrobial activities of some new 1,2,3-triazole derivatives.
April 2010, Molecules (Basel, Switzerland),
Pramod S Phatak, and Rajubai D Bakale, and Ravibhushan S Kulkarni, and Sambhaji T Dhumal, and Prashant P Dixit, and Vagolu Siva Krishna, and Dharmarajan Sriram, and Vijay M Khedkar, and Kishan P Haval
Design, synthesis and antimicrobial activities of some new quinoline derivatives carrying 1,2,3-triazole moiety.
September 2010, European journal of medicinal chemistry,
Copied contents to your clipboard!